BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maccora I, dell’Anna MP, Vannacci A, Simonini G. Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert Opinion on Drug Safety 2020;19:661-71. [DOI: 10.1080/14740338.2020.1763300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Demirkan FG, Ulu K, Öztürk K, Karadağ ŞG, Özdel S, Sönmez HE, Çakmak F, Demir F, Sözeri B, Aktay Ayaz N. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opin Biol Ther 2021;:1-6. [PMID: 34730483 DOI: 10.1080/14712598.2021.2002296] [Reference Citation Analysis]
2 Failing CJ, Boehnke KF, Riebschleger M. Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2021;19:171. [PMID: 34903213 DOI: 10.1186/s12969-021-00656-5] [Reference Citation Analysis]
3 Maccora I, Fusco E, Marrani E, Ramanan AV, Simonini G. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology 2021;60:568-87. [DOI: 10.1093/rheumatology/keaa595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]